Abstract
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1007/s40273-023-01317-z
Journal: PharmacoEconomics | Publication Date: Oct 5, 2023 |
Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective.
Join us for a 30 min session where you can share your feedback and ask us any queries you have